Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weider marketing plans

This article was originally published in The Tan Sheet

Executive Summary

October print ads will support launch of Schiff Prostate Health, relaunch of Breast Health, supplement firm says Sept. 26 in announcing fiscal first quarter financial results. Hitting shelves by early December, Prostate Health contains lycopene, saw palmetto, calcium d-glucarate, while Breast Health features calcium d-glucarate, soy isoflavones, antioxidants. One-month supply of each will retail for $15, firm says. Weider plans to "significantly ramp up" marketing spending for Schiff line in mid-Q2. Net sales for division were up 1.5% to $41.2 mil. due to greater sales incentives, promotions, firm notes. Move Free line sales decreased 4.6% to $18.7 mil. due to private label competition. Move Free Triple Strength, which offers same amount of glucosamine/chondroitin in two tablets rather than three, debuted in late summer and is expanding distribution, Weider notes...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel